Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.58 |
| ▸ | KDR | P35968 | 7/20 | 0.51 |
| ▸ | EGFR | P00533 | 7/20 | 0.51 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.50 |
| ▸ | FLT4 | P35916 | 2/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | RET | P07949 | 2/20 | 0.47 |
| ▸ | KIF5B | P33176 | 2/20 | 0.47 |
| ▸ | MET | P08581 | 5/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4421590 | 0.94 | TRPA1 (0.61) | TRPA1KDREGFRIRAK1IRAK4 | |
| SCHEMBL7145586 | 0.83 | TRPA1 (0.53) | TRPA1KDREGFRIRAK1IRAK4 | |
| SCHEMBL8815929 | 0.83 | IRAK1 (0.59) | TRPA1KDREGFRIRAK1IRAK4 | |
| SCHEMBL4692996 | 0.83 | TRPA1 (0.59) | TRPA1KDREGFRFLT4CSF1R | |
| SCHEMBL30002061 | 0.82 | TRPA1 (0.61) | TRPA1KDREGFRIRAK1IRAK4 | |
| SCHEMBL4028296 | 0.82 | TRPA1 (0.61) | TRPA1KDREGFRIRAK1IRAK4 | |
| SCHEMBL18550520 | 0.82 | TRPA1 (0.61) | TRPA1KDREGFRIRAK1IRAK4 | |
| SCHEMBL7145589 | 0.82 | TRPA1 (0.45) | TRPA1KDREGFRIRAK1IRAK4 | |
| SCHEMBL21408242 | 0.82 | MET (0.58) | KDREGFRMET | |
| SCHEMBL30216641 | 0.82 | MET (0.58) | KDREGFRMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225111-A1 | Therapy | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225111-A1 | Therapy | VEGFA, AQP1, FLT1 | TRPA1 2378/4885KDR 39/4885EGFR 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.